A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Suspended
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 15 Feb 2018 Status changed from recruiting to suspended.
    • 11 Sep 2017 Planned number of patients changed from 40 to 100.
    • 25 Jun 2017 Results (n=16) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top